Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) - Total Assets
Based on the latest financial reports, Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) holds total assets worth $196.34K USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Lakewood-Amedex Biotherapeutics Inc. Com cash flow conversion for how efficiently the company converts equity into cash flow.
Lakewood-Amedex Biotherapeutics Inc. Common Stock - Total Assets Trend (2023–2025)
This chart illustrates how Lakewood-Amedex Biotherapeutics Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See LABT stock price for real-time trading data and today's change.
Lakewood-Amedex Biotherapeutics Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Lakewood-Amedex Biotherapeutics Inc. Common Stock's total assets of $196.34K consist of 63.4% current assets and 36.6% non-current assets. Explore Lakewood-Amedex Biotherapeutics Inc. Com current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 49.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2023–2025)
This chart illustrates how Lakewood-Amedex Biotherapeutics Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lakewood-Amedex Biotherapeutics Inc. Common Stock's current assets represent 63.4% of total assets in 2025, a decrease from 94.0% in 2023.
- Cash Position: Cash and equivalents constituted 49.1% of total assets in 2025, up from 36.7% in 2023.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2023.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Lakewood-Amedex Biotherapeutics Inc. Common Stock Competitors by Total Assets
Key competitors of Lakewood-Amedex Biotherapeutics Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Galecto Inc
NASDAQ:GLTO
|
USA | $535.44 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
ABL Bio Inc
KQ:298380
|
Korea | ₩273.72 Billion |
Lakewood-Amedex Biotherapeutics Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.02 | 1.55 | 1.55 |
| Quick Ratio | 0.02 | 1.55 | 1.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.98 Million | $273.35K | $273.35K |
Lakewood-Amedex Biotherapeutics Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Lakewood-Amedex Biotherapeutics Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 2.88 |
| Asset Growth Rate (YoY) | -55.0% |
| Total Assets | $481.60K |
| Market Capitalization | $1.39 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Lakewood-Amedex Biotherapeutics Inc. Common Stock's assets at a significant premium (2.88x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Lakewood-Amedex Biotherapeutics Inc. Common Stock's assets decreased by 55.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lakewood-Amedex Biotherapeutics Inc. Common Stock (2023–2025)
The table below shows the annual total assets of Lakewood-Amedex Biotherapeutics Inc. Common Stock from 2023 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $481.60K | -55.02% |
| 2024-12-31 | $1.07 Million | -84.47% |
| 2023-12-31 | $6.89 Million | -- |
About Lakewood-Amedex Biotherapeutics Inc. Common Stock
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic f… Read more